TRINETRA › Sectors › Chemicals
Tatva Chintan Pharma Chem Limited (TATVA) — share price, P/E and fundamentals
Tatva Chintan Pharma Chem Limited (NSE: TATVA) closed at ₹1,643.90 on 30 Oct 2026, +23.6% over one year, against a 52-week range of ₹1,044.10 – ₹2,113.60.
In the quarter ended 30 Sept 2026 (consolidated, filed 19 Oct 2026) it reported revenue of ₹217 cr and net profit of ₹21 cr, a 9.9% net margin; revenue grew 75.9% and profit grew 111.8% year on year.
On four consecutive filed quarters its trailing P/E is 61.1; since 2 May 2025 its own P/E has ranged from 58.3 to 651.1 (median 95.1), and today's reading is higher than 1% of those 370 trading days.
From the balance sheet dated 30 Sept 2026: return on equity 10.5%, ROCE 15.4%, debt-to-equity 0.21, Piotroski F-score 4 of 9.
Against 43 Chemicals peers on NSE: Net margin higher than 49% of 43 sector peers; PBT margin higher than 51% of 43 sector peers; ROE higher than 34% of 41 sector peers.
Key figures
| Last close | ₹1,643.90 (30 Oct 2026) |
|---|---|
| Change 1 month / 6 months / 1 year | -4.9% / +29.5% / +23.6% |
| 52-week low – high | ₹1,044.10 – ₹2,113.60 |
| Market capitalisation | ₹3,845 cr |
| Trailing P/E | 61.1 |
| Price / book | 4.72 |
| EV / EBITDA | 30.5 |
| Earnings yield | 1.6% |
| TTM EPS | ₹26.90 |
| TTM net profit | ₹63 cr |
| Quarter revenue | ₹217 cr |
| Quarter net profit | ₹21 cr |
| Net margin | 9.9% |
| Revenue growth (YoY) | +75.9% |
| Profit growth (YoY) | +111.8% |
| Return on equity | 10.5% |
| ROCE | 15.4% |
| Debt / equity | 0.21 |
| Current ratio | 1.59 |
| Free cash flow | ₹-35 cr |
| Piotroski F-score | 4 / 9 |
| Average daily turnover (50 days) | ₹11.9 cr |
Against Chemicals peers
| Metric | TATVA | Peer median | Percentile |
|---|---|---|---|
| Net margin | 9.87 | 9.91 | 49 |
| PBT margin | 13.32 | 13.29 | 51 |
| ROE | 10.53 | 13.64 | 34 |
| ROCE | 15.38 | 16.08 | 44 |
| Debt / equity | 0.21 | 0.23 | 46 |
| FCF margin | -8.98 | 0.76 | 21 |
| Cash conversion | -0.10 | 0.95 | 18 |
| Trailing P/E | 61.12 | 34.59 | 76 |
Questions
What is the P/E ratio of Tatva Chintan Pharma Chem Limited?
Tatva Chintan Pharma Chem Limited's trailing P/E is 61.1, using the close of 30 Oct 2026 and earnings over the four filed quarters to 30 Sept 2026. Since 2 May 2025 its P/E has ranged 58.3–651.1.
What were Tatva Chintan Pharma Chem Limited's latest quarterly results?
For the quarter ended 30 Sept 2026, Tatva Chintan Pharma Chem Limited reported revenue of ₹217 cr and net profit of ₹21 cr (consolidated), filed with the exchange on 19 Oct 2026.
What is Tatva Chintan Pharma Chem Limited's ROE?
Return on equity is 10.5% based on the balance sheet dated 30 Sept 2026.
Does Tatva Chintan Pharma Chem Limited have debt?
Debt-to-equity is 0.21 on the balance sheet dated 30 Sept 2026.
What is TATVA's 52-week high and low?
Over the last 52 weeks to 30 Oct 2026, TATVA traded between ₹1,044.10 and ₹2,113.60.
Other Chemicals stocks
- Solar Industries India Limited (SOLARINDS)
- Pidilite Industries Limited (PIDILITIND)
- SRF Limited (SRF)
- Coromandel International Limited (COROMANDEL)
- Linde India Limited (LINDEINDIA)
- Gujarat Fluorochemicals Limited (FLUOROCHEM)
- Navin Fluorine International Limited (NAVINFLUOR)
- Fertilizers and Chemicals Travancore Limited (FACT)
- UPL Limited (UPL)
- Himadri Speciality Chemical Limited (HSCL)
- Aether Industries Limited (AETHER)
- Deepak Nitrite Limited (DEEPAKNTR)
Source: consolidated SEBI Integrated Filing for the quarter ended 30 Sept 2026 and NSE daily closes. Open the interactive terminal view for charts and the full statements.
TRINETRA is a research and education tool. Nothing on this site is investment advice or a recommendation to buy or sell any security. Markets carry risk; do your own research and consult a SEBI-registered adviser before investing. Figures are as filed with NSE/SEBI and as of the dates shown; they are not live prices.